Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-17
2005-05-17
Travers, Russell (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S258100, C514S259500, C514S260100, C514S049000
Reexamination Certificate
active
06894056
ABSTRACT:
A method for alleviating chronic fatigue syndrome with the administration of antiviral agents. Based on clinical tests, chronic fatigue syndrome is a persistent herpes virus infection including incomplete virus multiplication and thus administration of antiviral agents are shown to alleviate the symptoms associated with the disorder. Based on therapeutic trials, patients receiving the recommended antiviral treatment, have experienced significant reduction or elimination of the symptoms associated with chronic fatigue syndrome. A method of diagnosis of the chronic fatigue syndrome is further disclosed.
REFERENCES:
patent: 4544634 (1985-10-01), Krenitsky
patent: 4695570 (1987-09-01), Krenitsky
patent: 4897394 (1990-01-01), Zimmerman et al.
patent: 4957924 (1990-09-01), Beauchamp
patent: 5055296 (1991-10-01), Wagle et al.
patent: 5061708 (1991-10-01), Krenitsky
patent: 5079252 (1992-01-01), Beauchamp
patent: 5189022 (1993-02-01), Bridge et al.
patent: 5206008 (1993-04-01), Loria
patent: 5213106 (1993-05-01), Lerner
patent: 5267570 (1993-12-01), Preston
patent: 5312817 (1994-05-01), Snorrason
patent: 5357968 (1994-10-01), Lerner
patent: 5405850 (1995-04-01), Blumenkopf
patent: 5426028 (1995-06-01), Levy et al.
patent: 5461042 (1995-10-01), Loria
patent: 5464020 (1995-11-01), Lerner
patent: 5491150 (1996-02-01), Aoki et al.
patent: 5538856 (1996-07-01), Levy et al.
patent: 5545550 (1996-08-01), Grossberg et al.
patent: 5545670 (1996-08-01), Bissbort et al.
patent: 5872123 (1999-02-01), Lerner
patent: 6258818 (2001-07-01), Lerner
Fields Virology 3rd Edition. Feild et al Eds. Lippincott-Racen, Phil. Pa, 1995, pp. 2834-2835.*
“Perspectives on Interactions of Acyclovir with Epstein-Barr and Other Herpes Virus” Joseph S. Pagano. M.D.. and Alok K. Datta. Ph.D.Acyclovir Symposium-The American Journal of Medicine1982: 73: pp. 18-26.
“Valacyclovir HC1 (Valtrex) Provides Simplified Dosing and Increased Efficacy in the Treatment of Herpe's Virus Infections”Int. Pharm. Abstr.1994: 31:2244-5. Abstract No. 3111836.
“The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study”, Keiji Fukuda, M.D., et al Annals of Internal Medicine, vol. 121, No. 12, pp. 953-959.
“Lack of Evidence for Infection with Known Human and Animal Retroviruses in Patients with Chronic Fatigue Syndrome”, Clin. Infec. Disease 18, Suppl. 1, 1994, pp. S121-125.
“Long-Term Serological Follow-Up of Patients for Epstein-Barr Virus After Recovery from Infectious Mononucleosis”, The Journal of Infectious Diseases, S. Horwitz. vol. 151, No. 6. Jun. 1985, pp. 1150-1153.
“Studies on Enterovirus in Patients with Chronic Fatigue Syndrome”, J.W. Gow.et al Clinical Infectious Diseases. 1994: 18 (Suppl. 1), pp. S126-129.
“Molecular Biology and Immunology of Cytomegalovirus”, Paul D. Griffiths and Jane E. Grundy, Biochem. J., (1987) vol. 241, pp. 313-324.
“Herpes Simplex Encephalitis-Vidarabine Therapy and Diagnostic Problems”, Richard J. Whitley, et al.: The New England Journal of Medicine, Feb. 5, 1981: vol. 304, No. 6, pp. 313-318.
“In Situ Detection of Human Cytomegalovirus Immediately-Early Gene Transcripts, etc.” Tzyy-Choou Wu, et al, AIDS, 1992, vol. 6, No. 8, pp. 777-785.
“Cytomegalovirus as a Possible Cause of a Disease Resembling Infectious Mononucleosis” E. Klemola and L. Kaariainen, British Medical Journal, 1965, vol. 2, pp. 1099-1102.
“Infectious Mononucleosis”, James C. Niederman, et al, Journal of the American Medical Association, 1968, vol. 203, No. 3, pp. 205-209.
“Medical Consequences of Persistent Viral Infection”, Peter Southern and Michael B.A. Oldstone, New England Journal of Medicine, vol. 314, No. 6, pp. 359-367.
“Lack of Evidence for Infection with Known Human and Anmial Retroviruses in Patients with Chronic Fatigue Syndrome”, Walid Heneine, et al. Clinical Infectious Diseases 1994: 18 (Suppl. 1), pp. S121-S125.
“Repetitively Negative Changine T Waves at 24-h Electrocardiographic Monitors in Patients with the Chronic Fatigue Syndrome”, A. Martin Lerner, et al: Chest vol. 104, No. 5, Nov. 1993, pp. 1417-1421.
“Abnormal Left Ventricular Myocardial Dynamics in Eleven Patients with Chronic Fatigue Syndrome”, Clinical Nuclear Medicine, Aug. 1994, vol. 19, No. 8, pp. 675-677.
“Immune Surveillance Against Epstein-Barr Virus”, Denis J. Moss. et al. Immunology, vol. 4. 1992. pp. 97-104.
“A Second Site for Epstein-Barr Virus Shedding: The Uterine Cervix”, John W. Sixbey, et al. The Lancet, Nov. 1986, pp. 1122-1124.
“Prolonged Inhibitory Effect of 9-(1.3-Dihydroxy-2-Propoxymethyl)Guanine Against Replication of Epstein-Barr Virus”, Jung-Chung Lin, et al, Journal of Virology, Apr. 1984. vol. 50. No. 1. pp. 50-55.
“Epstein-Barr Virus Replication in Oropharyngeal Epithelial Cells”, John W. Sixbey, et al. The New England Journal of Medicine. vol. 310. No. 19. 1984. pp. 1225-1230.
“Chronic Epstein-Barr Virus Infection Associated with Fever and Interstitial Pneumonitis”, Robert T. Schooley, et al. Annals of Internal Medicine, 1986, vol. 104, pp. 636-643.
“Long-Term Serological Follow-Up of Patients for Epstein-Barr Virus After Recovery from Infectious Mononucleosis”. Charles A. Horowitz, et al, The Journal of Infectious Diseases. vol. 151, No. 6, Jun. 1985, pp. 1150-1153.
“Is Neurally Mediated Hypotension an Unrecognised Cause of Chronic Fatigue?”, Peter C. Rowe, et al. The Lancet, vol. 345, pp. 623-624.
“Chronic Fatigue Syndrome”, Priciples and Practice of Infectious Diseases-4th Ed. , R. T. Schooley, 1995, pp. 1306-1310.
“Acyclovir Treatment of the Chronic Fatigue Syndrome”, Stephen E. Straus, et al, The New England Journal of Medicine, vol. 319, No. 26, pp. 1692-1698.
“The Chronic Fatigue Syndrome—One Entity or Many?”, Morton N. Swartz. The New England Journal of Medicine, vol. 319, No. 26, 1988, pp. 1726-1728.
“The Relationship Between Neurally Mediated Hypotension and the Chronic Fatigue Syndrome”, Issam-Bou-Holaigah, et al, Journal of The American Medical Association, vol. 274, No. 12, pp. 961-967.
“A Cluster of Patients with a Chronic Mononucleosis-like Syndrome: Is Epstein-Barr Virus the Cause?”, G.P. Holmes, et al, Journal of The American Medical Association, 1987, vol. 257, No. 17, pp. 2297-2302.
“Frequency of ‘Chronic Active Epstein-Barr Virus Infection’ in a General Medical Practice”, Dedra Buchwald, et al, Journal of The American Medical Association, 1987, vol. 257, No. 17, pp. 2303-2307.
“The Epstein-Barr Virus: Host Balance in Acute Infectious Monocleosis Patients Receiving Acyclovir Anti-Viral Therapy”, Q.Y. Yao, Int. J. Cancer. 1989. vol. 43. pp. 61-66.
“A Double-Blind. Placebo-Controlled Trial of Intravenous Immunoglobulin Therapy in Patients with Chronic Fatigue Syndrome”, Andrew Lyod, et al, The American Journal of Medicine, 1990, vol. 89, pp. 561-568.
“A Controlled Trial of Intravenous Immunoglobulin G in Chronic Fatigue Syndrome” P.K. Peterson, et al. The American Journal of Medicine. 1990. vol. 89. pp. 554-560.
“Chronic Fatigue Syndrome: A Working Case Definition”. G.P. Holmes, et al Animals of Internal Medicine, 1988, vol. 108, pp. 387-389.
“Leukocyte-Transforming Agent: Prolonged Excretion by Patients with Mononucleosis and Excretion by Normal Individuals”, H. Dean Golden, et al. The Journal of Infectious Diseases, 1973, vol. 127. No. 4. pp. 471-473.
“Enhanced Serological and Virological Findings of Epstein-Barr Virus in Patients with AIDS and AIDS-Related Complex”, Ciro V. Sumaya. et al. The Journal of Infectious Diseases. 1986, vol. 154, No. 5, pp. 864-870.
“Human Herpes Virus-6: Clinical Implications of a Recently Discovered, Ubiquitous Agent”, Charles T. Leach. The Journal of Pedi
Brooks & Kushman P.C.
Travers Russell
LandOfFree
Method for diagnosing and alleviating the symptoms of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for diagnosing and alleviating the symptoms of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for diagnosing and alleviating the symptoms of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3387366